氟哌噻吨美利曲辛辅助治疗难治性胃食管反流病疗效观察

Observation of curative effect of flupentixol melitracen as an adjuvant treatment for the patients with refractory gastroesophageal reflux disease

目的探讨氟哌噻吨美利曲辛辅助治疗难治性胃食管反流病的临床疗效。方法 142例难治性胃食管反流病患者采用随机数字表法分成观察组和对照组。对照组70例给予埃索美拉唑和莫沙必利治疗;观察组72例在对照组基础上加用氟哌噻吨美利曲辛。两组均治疗8周,观察临床疗效、胃食管反流病问卷评分、汉密尔顿焦虑和抑郁评分变化。停药后随访6月,观察临床症状复发率。结果观察组临床症状缓解率高于对照组(P<0.05)。两组治疗8周后胃食管反流病问卷评分、汉密尔顿焦虑和抑郁评分均有不同程度下降,且观察组下降程度高于对照组(P<0.05)。停药随访6月,观察组临床症状复发率低于对照组(P<0.05)。结论氟哌噻吨美利曲辛能够提高埃索美拉唑和莫沙必利治疗难治性胃食管反流病临床疗效和减少临床症状复发率。

Objective To investigate the clinical efficacy of flupentixol melitracen as an adjuvant treatment in the patients with refractory gastroesophageal reflux disease. Methods One hundred and forty-two patients were assigned into observation group and control group. The control group （n = 70） was treated with esomeprazole and mosapride while the observation group （n = 72） was treated with esomeprazole and mosapride plus flupentixol melitracen. The therapeutic course was 8 weeks. The clinic symptom,gastroesophageal reflux disease questionnaire （GerdQ） score, Hamilton anxiety scale （HAMA） score and Hamilton depression scale （HAMD） score were assessed. The clinical symptom recurrence rate was also assessed after 6 months of drug withdrawal. Results The clinical symptom remission rate in the observation was higher than the control group （p 〈 0. 05 ）. After 8 weeks of treatment,the GerdQ score,HAMA score and HAMD score were improved to some extent in both groups. However,the improvement in the observation group was better than the control group （P 〈0. 05）. After 6 months of follow-up, the clinical symptom recurrence rate in the observation group was lower than that in the control group （ P 〈 0. 05）. Conclusion Flupentixol melitracen could increase the curative effect of esomeprazole＇ and mosapride for refractory gastroesophageal reflux disease and reduce the recurrence rate.